Cytotoxic chemotherapy for metastatic renal cell carcinoma

Urologe - Ausgabe A

Volumn 43, Issue SUPPL. 2, 2004, Pages

  Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 2; NUCLEOSIDE ANALOG; THALIDOMIDE; TROXACITABINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG INFUSION; DRUG RESPONSE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYCYTIDINE; FLOXURIDINE; FLUOROURACIL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 4744338650     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-004-0608-4     Document Type: Conference Paper

References (10)

1. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408-417
2. Kish JA, Wolf M,Crawford ED, et al (1994) Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74:916-919
3. Mertens WC, Eisenhauer EA, Moore M, et al (1993) Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4:331-332
4. Weissbach L, de Mulder P, Osieka R, et al (1992) Phase II study of gemcitabine in renal cancer. Proc Am Soc Clin Oncol 11:219
5. Townsley CA, Chi K, Ernst DS, et al (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 21:1524-1529
6. Rini BI, Vogelzang NJ, Dumas MC, Wade JL, 3rd, Taber DA, Stadler WM (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419-2426
7. Ryan CW, Vogelzang NJ, Stadler WM (2002) A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 94:2602-2609
8. Desai AA,Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM (2002) A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95:1629-1636
9. George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM (2002) A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 13:116-120
10. Stadler WM, Huo D, George C, et al (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170:1141-1145